ABOUT VISIONAIRE
Visionaire Products creates devices that change how clinicians sample and analyze ocular fluid. OcuTap is a single-use tool with a simple attach-and-prime setup, designed for single-handed anterior chamber paracentesis, with a detachable vial that ships directly to the lab. We work closely with ophthalmologists and labs to meet clinical needs, validate with evidence, and build user-friendly devices.
A board-certified ophthalmologist and co-founder of Visionaire Products, she is a retina specialist with an MBA in healthcare marketing. She has served as principal investigator on numerous national clinical trials, secured over $4.5 million in NSF and Defense Health Agency grant funding, and co-founded InnSight Technology, advising medical device companies on novel ophthalmology treatments.
Brings 40+ years of experience launching and commercializing new technologies, including as General Manager of Nissha's printed electronics division. Since joining Visionaire in 2019, he has led manufacturing strategy, materials sourcing, and NSF Small Business Innovation Research (SBIR) Phase I/II grants, driving the OcuTap device toward successful commercialization.
Drives technical development across device design, testing, and technology commercialization. He led verification and validation efforts supporting FDA 510(k) submission of the OcuTap and leads early-stage design of Visionaire's next-generation ophthalmic diagnostic platform. He earned both Bachelor's and Master's degrees in Bioengineering from the University of Pittsburgh.
Serves as a strategic Clinical Advisor for Visionaire, lending clinical and industry expertise to OcuTap's development. Currently Chief Medical Officer at Nextech Systems and Partner at Sight360, he brings deep ophthalmic and anterior chamber procedural knowledge that helps refine the device's performance and path to commercialization.
Serving as the Director of Operations, Quality and Regulatory at Visionaire, Madeline oversees quality systems, design controls, and regulatory compliance for the OcuTap device. Madeline brings over 10 years of medical device quality engineering experience from roles at iotaMotion, NuVasive, and Smith & Nephew. She earned her B.S. in Biomedical Engineering from the University of Iowa.
Visionaire has secured $1.25 million in non-dilutive funding through the National Science Foundation (NSF) Small Business Innovation Research Phase I and Phase II awards. This funding reflects the NSF’s recognition of OcuTap’s technical merit and supports our work toward FDA clearance.
OcuTap is pending U.S. Food and Drug Administration (FDA) clearance, anticipated by the end of 2026. Sign up to get updates and we’ll email you when there’s meaningful news to share.